426219-18-3

Basic information

• Product Name: TAK-700
• Synonyms: (S)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-e]imidazol-7-yl)-N-methyl-2-naphthamide;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide TAK-700 (Orteronel);6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-Naphthalenecarboxamide;6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methy;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide
• CAS NO: 426219-18-3
• Molecular Formula: C18H17N3O2
• Molecular Weight: 307.34648
• Product Categories: Inhibitors;Inhibitor
• Mol File: 426219-18-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TAK-700(CAS DataBase Reference)
• NIST Chemistry Reference: TAK-700(426219-18-3)
• EPA Substance Registry System: TAK-700(426219-18-3)

Safety Data

• Hazardous Substances Data: 426219-18-3(Hazardous Substances Data)

Usage

General Description

TAK-700, also known as orteronel, is a selective inhibitor of 17α-hydroxylase/C17,20-lyase (CYP17). It is a synthetic, nonsteroidal, androgen biosynthesis inhibitor that is used in the treatment of advanced prostate cancer. TAK-700 works by decreasing the production of androgens, which are hormones that can stimulate the growth of prostate cancer cells. Additionally, TAK-700 has shown promising results in clinical trials and is being studied for its potential use in other hormone-related cancers, such as breast and ovarian cancer. However,

Upstream product

• 566200-79-1 6-[(1S)-1,3-dihydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 
• 566200-98-4 tert-butyl (3S)-3-hydroxy-3-{6-[(methylamino)carbonyl]-2-naphthyl}-3-(1-trityl-1H-imidazol-4-yl)propanoate 
• 337521-39-8 N-methyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 
• 566200-96-2 6-[hydroxy(1-trityl-1H-imidazol-4-yl)methyl]-N-methyl-2-naphthamide 
• 426219-35-4 6-bromo-N-methyl-2-naphthamide 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 57531-35-8 C₆H₆N₂O 
• 1346155-45-0 3-bromo-1-(1H-imidazol-4-yl)-1-propanone hydrobromide 
• 1346155-60-9 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N,N-diisopropyl-2-naphthamide 
• 74-89-5 methylamine 
• 426219-47-8 N,N-diisopropyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 
• 1346155-54-1 N,N-diisopropyl-6-[1-hydroxy-1-(1-trityl-1H-imidazol-4-yl)methyl]-2-naphthamide 
• 426219-43-4 5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one 

Downstream Products

• 566939-85-3 Orteronel 
• 752243-39-3 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide 
• 426219-53-6 2C₁₀H₁₁NO₅*C₁₈H₁₇N₃O₂ 

Relevant articles and documents

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

A series of 1,1-diarylalkene derivatives were prepared to optimize the properties of CC-5079 (1), a dual inhibitor of tubulin polymerization and phosphodiesterase 4 (PDE4). By using the 3-ethoxy-4-methoxyphenyl PDE4 pharmacophore as one of the aromatic ri

PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME

The present invention provides an industrially advantageous process for producing a steroid C17,20 lyase inhibitor represented by the general formula (I): and a Reformatsky reagent in a stable form suitable for the process.In the present invention, a compound represented by the general formula (I) is produced by reducing a specific β-hydroxy ester compound derivative or a salt thereof obtained from a specific carbonyl compound in a Reformatsky reaction in the presence of a metal hydride complex and a metal halide, and then subjecting it to a ring-closing reaction. In the above Reformatsky reaction, it is useful to use a stable solution of a compound represented by the general formula BrZnCH2COOC2H5 or a crystal of the compound which is represented by the formula (BrZnCH2COOC2H5·THF)2.